Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up

The objective of this study was to determine the impact of a pharmaceutical care (PC) program in a sample of public outpatients with metabolic syndrome (MS) who were being treated in Brazil's health system; the patients were randomized into PC or standard care. The pharmacotherapy follow-up (PF) was performed in a total of 120 patients with type 2 diabetes for 6 months. Adherence to treatment (measured with the Morisky test), negative outcomes associated with medication (NOM) and anthropometric and biochemical parameters were measured before and after PF. The Framingham scoring method was used to estimate changes in 10-year coronary heart disease risk scores in all patients. Ninety-six of 120 patients had characteristics of MS and were randomized into two groups (G): the control group (CG: 36) and the intervention group (IG: 38). Among the MS patients, 100% were taking a glucose-lowering drug; many were also taking anti-hypertensive drugs (CG: 72%; IG: 73%), and some patients were also taking hypolipemic drugs (CG: 12.0%; IG: 14.7%). Only 20.7% of the IG patients were considered adherent to their prescribed drugs. In the CG, an increase of coronary heart disease (CHD) risk (22±2 to 26±3; p<0.05) was observed, while in the IG, there was a reduction in CHD risk (22±2 to 14±2%; p<0.01). The PC program administered to patients with MS monitored through the primary healthcare services of the Brazilian public health system improved patient health, resulting in clinical improvements and a decrease in cardiovascular risk in IG patients over a period of ten years.

Saved in:
Bibliographic Details
Main Authors: Plaster,Camila Pedro, Melo,Danilo Travassos, Boldt,Veraci, Cassaro,Karla Oliveira dos Santos, Lessa,Fernanda Campos Rosetti, Boëchat,Giovanna Assis Pererira, Bissoli,Nazaré Souza, Andrade,Tadeu Uggere de
Format: Digital revista
Language:English
Published: Universidade de São Paulo, Faculdade de Ciências Farmacêuticas 2012
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502012000300010
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1984-82502012000300010
record_format ojs
spelling oai:scielo:S1984-825020120003000102012-10-18Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-upPlaster,Camila PedroMelo,Danilo TravassosBoldt,VeraciCassaro,Karla Oliveira dos SantosLessa,Fernanda Campos RosettiBoëchat,Giovanna Assis PereriraBissoli,Nazaré SouzaAndrade,Tadeu Uggere de Pharmaceutical service Metabolic syndrome/cardiovascular risk Drug therapy follow-up Medicines/associated negative outcomes The objective of this study was to determine the impact of a pharmaceutical care (PC) program in a sample of public outpatients with metabolic syndrome (MS) who were being treated in Brazil's health system; the patients were randomized into PC or standard care. The pharmacotherapy follow-up (PF) was performed in a total of 120 patients with type 2 diabetes for 6 months. Adherence to treatment (measured with the Morisky test), negative outcomes associated with medication (NOM) and anthropometric and biochemical parameters were measured before and after PF. The Framingham scoring method was used to estimate changes in 10-year coronary heart disease risk scores in all patients. Ninety-six of 120 patients had characteristics of MS and were randomized into two groups (G): the control group (CG: 36) and the intervention group (IG: 38). Among the MS patients, 100% were taking a glucose-lowering drug; many were also taking anti-hypertensive drugs (CG: 72%; IG: 73%), and some patients were also taking hypolipemic drugs (CG: 12.0%; IG: 14.7%). Only 20.7% of the IG patients were considered adherent to their prescribed drugs. In the CG, an increase of coronary heart disease (CHD) risk (22±2 to 26±3; p<0.05) was observed, while in the IG, there was a reduction in CHD risk (22±2 to 14±2%; p<0.01). The PC program administered to patients with MS monitored through the primary healthcare services of the Brazilian public health system improved patient health, resulting in clinical improvements and a decrease in cardiovascular risk in IG patients over a period of ten years.info:eu-repo/semantics/openAccessUniversidade de São Paulo, Faculdade de Ciências FarmacêuticasBrazilian Journal of Pharmaceutical Sciences v.48 n.3 20122012-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502012000300010en10.1590/S1984-82502012000300010
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Plaster,Camila Pedro
Melo,Danilo Travassos
Boldt,Veraci
Cassaro,Karla Oliveira dos Santos
Lessa,Fernanda Campos Rosetti
Boëchat,Giovanna Assis Pererira
Bissoli,Nazaré Souza
Andrade,Tadeu Uggere de
spellingShingle Plaster,Camila Pedro
Melo,Danilo Travassos
Boldt,Veraci
Cassaro,Karla Oliveira dos Santos
Lessa,Fernanda Campos Rosetti
Boëchat,Giovanna Assis Pererira
Bissoli,Nazaré Souza
Andrade,Tadeu Uggere de
Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up
author_facet Plaster,Camila Pedro
Melo,Danilo Travassos
Boldt,Veraci
Cassaro,Karla Oliveira dos Santos
Lessa,Fernanda Campos Rosetti
Boëchat,Giovanna Assis Pererira
Bissoli,Nazaré Souza
Andrade,Tadeu Uggere de
author_sort Plaster,Camila Pedro
title Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up
title_short Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up
title_full Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up
title_fullStr Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up
title_full_unstemmed Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up
title_sort reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up
description The objective of this study was to determine the impact of a pharmaceutical care (PC) program in a sample of public outpatients with metabolic syndrome (MS) who were being treated in Brazil's health system; the patients were randomized into PC or standard care. The pharmacotherapy follow-up (PF) was performed in a total of 120 patients with type 2 diabetes for 6 months. Adherence to treatment (measured with the Morisky test), negative outcomes associated with medication (NOM) and anthropometric and biochemical parameters were measured before and after PF. The Framingham scoring method was used to estimate changes in 10-year coronary heart disease risk scores in all patients. Ninety-six of 120 patients had characteristics of MS and were randomized into two groups (G): the control group (CG: 36) and the intervention group (IG: 38). Among the MS patients, 100% were taking a glucose-lowering drug; many were also taking anti-hypertensive drugs (CG: 72%; IG: 73%), and some patients were also taking hypolipemic drugs (CG: 12.0%; IG: 14.7%). Only 20.7% of the IG patients were considered adherent to their prescribed drugs. In the CG, an increase of coronary heart disease (CHD) risk (22±2 to 26±3; p<0.05) was observed, while in the IG, there was a reduction in CHD risk (22±2 to 14±2%; p<0.01). The PC program administered to patients with MS monitored through the primary healthcare services of the Brazilian public health system improved patient health, resulting in clinical improvements and a decrease in cardiovascular risk in IG patients over a period of ten years.
publisher Universidade de São Paulo, Faculdade de Ciências Farmacêuticas
publishDate 2012
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502012000300010
work_keys_str_mv AT plastercamilapedro reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup
AT melodanilotravassos reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup
AT boldtveraci reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup
AT cassarokarlaoliveiradossantos reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup
AT lessafernandacamposrosetti reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup
AT boechatgiovannaassispererira reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup
AT bissolinazaresouza reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup
AT andradetadeuuggerede reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup
_version_ 1756437750706339840